Literature DB >> 16112646

Humoral detection of leukaemia-associated antigens in presentation acute myeloid leukaemia.

Barbara-Ann Guinn1, Elizabeth A Bland, Usman Lodi, Amanda P Liggins, Khalid Tobal, Sarah Petters, James W Wells, Alison H Banham, Ghulam J Mufti.   

Abstract

The serological analysis of recombinant cDNA expression libraries (SEREX) technique was used to immunoscreen a testes cDNA expression library with sera from newly diagnosed acute myeloid leukaemia (AML) patients. We used a testis cDNA library to aid our identification of cancer-testis (CT) antigens. We identified 44 antigens which we further immunoscreened with sera from AML, chronic myeloid leukaemia (CML), and normal donors. Eight antigens were solely recognised by patient sera including the recently described CT antigen, PASD1, and the cancer-related SSX2 interacting protein, SSX2IP. RT-PCR analysis indicated that we had identified three antigens which were expressed in patient bone marrow (BM) and peripheral blood (PB) but not in normal donor samples (PASD1, SSX2IP, and GRINL1A). Real-time PCR (RQ-PCR) confirmed the restricted expression of PASD1 in normal donor organs. Antigen presentation assays using monocyte-derived dendritic cells (mo-DCs) showed that PASD1 could stimulate autologous T-cell responses, suggesting that PASD1 could be a promising target for future immunotherapy clinical trials.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16112646     DOI: 10.1016/j.bbrc.2005.08.024

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  17 in total

1.  Role of scaffold protein afadin dilute domain-interacting protein (ADIP) in platelet-derived growth factor-induced cell movement by activating Rac protein through Vav2 protein.

Authors:  Yuri Fukumoto; Souichi Kurita; Yoshimi Takai; Hisakazu Ogita
Journal:  J Biol Chem       Date:  2011-10-25       Impact factor: 5.157

2.  CD4-positive T-helper cell responses to the PASD1 protein in patients with diffuse large B-cell lymphoma.

Authors:  Kamel Ait-Tahar; Amanda P Liggins; Graham P Collins; Andrew Campbell; Martin Barnardo; Maite Cabes; Charles H Lawrie; Donald Moir; Chris Hatton; Alison H Banham; Karen Pulford
Journal:  Haematologica       Date:  2010-09-17       Impact factor: 9.941

3.  A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies.

Authors:  Amanda P Liggins; Seah H Lim; Elizabeth J Soilleux; Karen Pulford; Alison H Banham
Journal:  Cancer Immun       Date:  2010-08-23

Review 4.  Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock?

Authors:  Maximilian Stahl; Benjamin Y Lu; Tae Kon Kim; Amer M Zeidan
Journal:  Target Oncol       Date:  2017-08       Impact factor: 4.493

5.  Cancer-testis antigens: the current status on antigen regulation and potential clinical use.

Authors:  Seah H Lim; Yana Zhang; Jian Zhang
Journal:  Am J Blood Res       Date:  2012-01-01

6.  An analogue peptide from the Cancer/Testis antigen PASD1 induces CD8+ T cell responses against naturally processed peptide.

Authors:  Nicola Hardwick; Sarah Buchan; Wendy Ingram; Ghazala Khan; Gisella Vittes; Jason Rice; Karen Pulford; Ghulam Mufti; Freda Stevenson; Barbara-ann Guinn
Journal:  Cancer Immun       Date:  2013-07-15

7.  Leukemia associated antigens: their dual role as biomarkers and immunotherapeutic targets for acute myeloid leukemia.

Authors:  Barbara-Ann Guinn; Azim Mohamedali; Ken I Mills; Barbara Czepulkowski; Michael Schmitt; Jochen Greiner
Journal:  Biomark Insights       Date:  2007-02-14

Review 8.  The SSX family of cancer-testis antigens as target proteins for tumor therapy.

Authors:  Heath A Smith; Douglas G McNeel
Journal:  Clin Dev Immunol       Date:  2010-10-11

Review 9.  Therapeutic use of Aldara in chronic myeloid leukemia.

Authors:  Annette M Marleau; Jeffrey H Lipton; Neil H Riordan; Thomas E Ichim
Journal:  J Transl Med       Date:  2007-01-25       Impact factor: 5.531

10.  SSX2IP promotes metastasis and chemotherapeutic resistance of hepatocellular carcinoma.

Authors:  Pu Li; Ying Lin; Yu Zhang; Zhenggang Zhu; Keke Huo
Journal:  J Transl Med       Date:  2013-03-01       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.